

**Appendix 1: References and other sources for excluded studies**

Study identification	References and other sources	Reason for exclusion
Katz	Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. <i>Neuropsychopharmacology</i> 2004;29:566-79. Katz MM, Houston JP, Brannan S, et al. A video method for the evaluation of antidepressant clinical and behavioural actions. <i>Int J Neuropsychopharmacol</i> 2006;9:327-36.	No data suitable for re-analysis
Ferguson	Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. <i>Int Clin Psychopharmacol</i> 2003;18:9-14.	No data suitable for re-analysis
PAR 29060.282 (MDUK 014/Tyrer)	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR_29060_282_MDUK014_Tyrer.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR_29060_282_MDUK014_Tyrer.pdf</a>	Study design not suitable for re-analysis
29060/012 (PAR 12-01)	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/I_29060_012.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/I_29060_012.pdf</a>	Study design not suitable for re-analysis
Lauritsen	Lauritzen L, Odgaard K, Clemmesen L, et al. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. <i>Acta Psychiatr Scand</i> 1996;94:241-51.	Patients received electroconvulsive therapy
Claghorn	Claghorn JL, Feighner JP. A double-blind comparison of paroxetine and imipramine in the long-term treatment of depression. <i>J Clin Psychopharmacol</i> 1993;13(6 Suppl 2): 23S-27S.	Study design not suitable for re-analysis
NKD10020	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_NKD10020.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_NKD10020.pdf</a>	Patients did not have major depression
MY-1061/BRL-029060/1-CPMS-327	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_MY1061_BRL_029060_1_CPMS_327.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_MY1061_BRL_029060_1_CPMS_327.pdf</a>	Patients did not have major depression
MY-1035/BRL-029060/1/CPMS-106	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1035_BRL029060_1_CPMS106.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1035_BRL029060_1_CPMS106.pdf</a>	Patients did not have major depression
MY-1034/BRL029060/1/CPMS-057	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1034_BRL029060_1_CPMS057.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1034_BRL029060_1_CPMS057.pdf</a>	Patients did not have major depression
29060/442	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_442.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_442.pdf</a>	Patients did not have major depression